[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE1398A1 - Compuestos de bencilaminopiperidina sustituidos - Google Patents

Compuestos de bencilaminopiperidina sustituidos

Info

Publication number
PE1398A1
PE1398A1 PE1996000625A PE00062596A PE1398A1 PE 1398 A1 PE1398 A1 PE 1398A1 PE 1996000625 A PE1996000625 A PE 1996000625A PE 00062596 A PE00062596 A PE 00062596A PE 1398 A1 PE1398 A1 PE 1398A1
Authority
PE
Peru
Prior art keywords
compounds
halogen
benzlaminopiperidine
substituted
complete
Prior art date
Application number
PE1996000625A
Other languages
English (en)
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE1398A1 publication Critical patent/PE1398A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I), EN DONDE: R ES HALOALQUILO C1-C8 O C(CF3)(R3)(R2), EN DONDE: R2 Y R3 SON HALOGENO, ENTRE OTROS, O R2 Y R3 COMPLETAN UN RADICAL ALQUIDENO C2-C6 OPCIONALMENTE SUSTITUIDO HASTA CON SIETE ATOMOS DE HALOGENO, (ESPECIFICAMENTE R ES CF3, DIFLUOROETILO, TRIFLUOROETILO O PENTAFLUOROETILO, ENTRE OTROS); R1 ES H, HALOGENO O ALCOXI C1-C6, O R Y R1 COMPLETAN UN CICLOALQUILO C4-C6 CONDENSADO; "X" ES METOXI, FENOXI O HALO, ENTRE OTROS; Ar ES FENILO. SON ANTAGONISTAS DE LA SUSTANCIA P, UTILES EN LA PREVENCION O TRATAMIENTO DE ENFERMEDADES DEL SNC, GASTROINTESTINALES O AFECCIONES CAUSADAS POR HELICOBACTER PYLORI, ENTRE OTROS
PE1996000625A 1995-08-24 1996-08-21 Compuestos de bencilaminopiperidina sustituidos PE1398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24

Publications (1)

Publication Number Publication Date
PE1398A1 true PE1398A1 (es) 1998-02-27

Family

ID=11004362

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2001000276A PE20010700A1 (es) 1995-08-24 1996-08-21 Compuestos de bencilaminopiperidina sustituidos
PE1996000625A PE1398A1 (es) 1995-08-24 1996-08-21 Compuestos de bencilaminopiperidina sustituidos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2001000276A PE20010700A1 (es) 1995-08-24 1996-08-21 Compuestos de bencilaminopiperidina sustituidos

Country Status (42)

Country Link
US (1) US6506775B1 (es)
EP (2) EP1114817B1 (es)
JP (1) JP3084069B2 (es)
KR (1) KR100288673B1 (es)
CN (1) CN1153764C (es)
AP (1) AP643A (es)
AR (1) AR006305A1 (es)
AT (2) ATE258166T1 (es)
AU (1) AU702698B2 (es)
BG (1) BG64126B1 (es)
BR (1) BR9609989A (es)
CA (1) CA2227814C (es)
CO (1) CO4480738A1 (es)
CZ (1) CZ297543B6 (es)
DE (2) DE69616817T2 (es)
DK (2) DK0861235T3 (es)
DZ (1) DZ2086A1 (es)
ES (2) ES2163017T3 (es)
HK (1) HK1014935A1 (es)
HR (1) HRP960386B1 (es)
HU (1) HU225480B1 (es)
IL (1) IL119078A (es)
IS (1) IS1947B (es)
MA (1) MA23961A1 (es)
MX (1) MX9801467A (es)
MY (1) MY114800A (es)
NO (1) NO310720B1 (es)
NZ (1) NZ308207A (es)
OA (1) OA10666A (es)
PE (2) PE20010700A1 (es)
PL (1) PL186773B1 (es)
PT (2) PT861235E (es)
RO (1) RO119299B1 (es)
RU (1) RU2152930C2 (es)
SI (2) SI1114817T1 (es)
SK (1) SK282925B6 (es)
TN (1) TNSN96107A1 (es)
TR (1) TR199800300T1 (es)
TW (1) TW340842B (es)
UA (1) UA48981C2 (es)
WO (1) WO1997008144A1 (es)
YU (1) YU49122B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
HUP0201135A3 (en) * 1999-05-06 2003-05-28 Pfizer Prod Inc Substituted benzolactam compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
ES2190781T3 (es) * 1999-05-21 2003-08-16 Pfizer Prod Inc Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
AU2004232799A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
JP2008500382A (ja) * 2004-05-21 2008-01-10 ファイザー・プロダクツ・インク (+)−(2s,3s)−3−(2−メトキシ−5−トリフルオロメトキシベンジルアミノ)−2−フェニル−ピペリジンの代謝産物
GEP20094640B (en) 2004-07-15 2009-03-10 Bristol Myers Squibb Co Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション p53活性を増大する置換ピペリジン及びその使用
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
EP0581777A1 (en) * 1991-03-26 1994-02-09 Pfizer Inc. Stereoselective preparation of substituted piperidines
CA2109613C (en) * 1991-06-20 1996-11-19 John Adams Lowe Iii Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
EP0780375B1 (en) * 1995-12-21 2002-09-11 Pfizer Inc. 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
HRP960386B1 (en) 2002-04-30
DZ2086A1 (fr) 2002-07-22
CN1153764C (zh) 2004-06-16
MX9801467A (es) 1998-05-31
ES2211684T3 (es) 2004-07-16
PE20010700A1 (es) 2001-07-09
UA48981C2 (uk) 2002-09-16
US6506775B1 (en) 2003-01-14
EP1114817B1 (en) 2004-01-21
TR199800300T1 (xx) 1998-06-22
HK1014935A1 (en) 1999-10-08
YU47896A (sh) 1998-12-23
HRP960386A2 (en) 1998-04-30
DE69616817T2 (de) 2002-04-04
IL119078A0 (en) 1996-11-14
SK20798A3 (en) 1999-03-12
NO310720B1 (no) 2001-08-20
CZ297543B6 (cs) 2007-02-07
NO980751L (no) 1998-02-23
AR006305A1 (es) 1999-08-25
OA10666A (en) 2002-11-25
AU702698B2 (en) 1999-03-04
YU49122B (sh) 2004-03-12
IL119078A (en) 2003-11-23
TW340842B (en) 1998-09-21
JPH10510554A (ja) 1998-10-13
NZ308207A (en) 1998-07-28
BG102288A (en) 1998-09-30
CA2227814A1 (en) 1997-03-06
JP3084069B2 (ja) 2000-09-04
PT861235E (pt) 2002-03-28
BG64126B1 (bg) 2004-01-30
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
BR9609989A (pt) 1999-07-06
CA2227814C (en) 2002-12-31
PT1114817E (pt) 2004-05-31
CZ52198A3 (cs) 1999-01-13
IS4644A (is) 1997-12-30
DK0861235T3 (da) 2001-12-27
CN1193961A (zh) 1998-09-23
IS1947B (is) 2004-10-13
KR19990044077A (ko) 1999-06-25
CO4480738A1 (es) 1997-07-09
PL325332A1 (en) 1998-07-20
SI1114817T1 (en) 2004-06-30
SK282925B6 (sk) 2003-01-09
AP9600850A0 (en) 1996-10-31
ES2163017T3 (es) 2002-01-16
EP1114817A1 (en) 2001-07-11
HUP9901159A3 (en) 2000-05-29
TNSN96107A1 (fr) 2005-03-15
EP0861235A1 (en) 1998-09-02
EP0861235B1 (en) 2001-11-07
KR100288673B1 (ko) 2001-05-02
DE69631390T2 (de) 2004-11-25
ATE258166T1 (de) 2004-02-15
AP643A (en) 1998-04-24
RU2152930C2 (ru) 2000-07-20
MY114800A (en) 2003-01-31
PL186773B1 (pl) 2004-02-27
HUP9901159A2 (hu) 1999-07-28
DK1114817T3 (da) 2004-04-26
ATE208377T1 (de) 2001-11-15
SI0861235T1 (en) 2002-04-30
AU5776996A (en) 1997-03-19
DE69616817D1 (de) 2001-12-13
RO119299B1 (ro) 2004-07-30
WO1997008144A1 (en) 1997-03-06
MA23961A1 (fr) 1997-04-01
NO980751D0 (no) 1998-02-23

Similar Documents

Publication Publication Date Title
PE1398A1 (es) Compuestos de bencilaminopiperidina sustituidos
PE28497A1 (es) Compuestos de naftilo, intermedios, composiciones y procedimientos
FR2617154B1 (fr) Procede d'obtention d'oxyde cerique et oxyde cerique a nouvelles caracteristiques morphologiques
OA08643A (fr) Composition détergente, visqueuse, diluable et son procédé d'obtention.
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
FI911411A (fi) Kiteinen, kidevedetön laktitoli ja menetelmä sen valmistamiseksi sekä sen käyttö
NO873351L (no) Haarrensemiddelblanding og anvendelse av denne.
ZA904196B (en) Process for the preparation of a pharmaceutical composition for the treatment of autoimmune diseases
FR2689504B1 (fr) Procédé de production d'hydrocarbures fluorés.
DK478788A (da) Polymorf modifikation af forbindelsen 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-8-azaspiro-(4.5) decan-7,9-dion
FI92320C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
DK0749438T3 (da) Hidtil ukendte silylforbindelser og deres anvendelse
KR880003941A (ko) 4,5-디하이드로옥사졸 유도체, 그의 제조방법 및 용도
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
ATE205203T1 (de) D4t polymorphe form i verfahren
FR2653771B1 (fr) Procede de preparation de l'azt (azido-3'-desoxy-3'-thymidine) et de composes apparentes.
PT924165E (pt) Processo para preparacao de sulfureto de sodio anidro
FR2753972B1 (fr) Composition de lactitol et son procede de preparation
HUT43594A (en) Process for production of new derivatives of izoxasole and medical compounds containing thereof
KR880005138A (ko) 신규 화합물들
MA21929A1 (fr) Procede de preparation d'un nouveau produit .
FR2597502B1 (fr) Procede de fabrication d'alcool avec recuperation des vinasses issues de la distillation
FR2654091B1 (fr) Procede de fabrication d'analogues de l'alumine-beta.
FI892911A (fi) Menetelmä terapeuttisesti käyttökelpoisen (+)-1-/(3,4,5-trimetoksi)bentsyylioksimetyyli/-1-fenyyli-N,N-dimetyyli-n-propyyliamiinin valmistamiseksi
EP0401049A3 (en) Beta-lactam elastase inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed